Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
PMAIP1, NOXA, PMA-induced protein 1, Protein Noxa, APR
Mouse, Human, Rat
(tested or 100% immunogen sequence identity)
IHC (1 µg/ml)
Western blot (0.5 - 1 µg/ml)
Performing IHC? See our complete line of Immunohistochemistry Reagents including antigen retrieval solutions, blocking agents
ABC Detection Kits and polymers, biotinylated secondary antibodies, substrates and more.
PMAIP1 / NOXA antibody was raised against synthetic peptide,17aa amino terminus of mouse Noxa (GenBank accession no. NP_067426).
Recognizes PMAIP1. Species cross-reactivity: Human, mouse and rat.
Suitable for use in Western Blot and Immunohistochemistry. Western Blot: 0.5-1 ug/ml. Immunohistochemistry: 1 ug/ml. Positive control: Human stomach cell lysate.
PBS, pH 7.2, 0.02% Sodium Azide
Short term: 4°C; Long term: Add glycerol (40-50%) -20°C.
Promotes activation of caspases and apoptosis. Promotes mitochondrial membrane changes and efflux of apoptogenic proteins from the mitochondria. Contributes to p53/TP53-dependent apoptosis after radiation exposure. Promotes proteasomal degradation of MCL1. Competes with BAK1 for binding to MCL1 and can displace BAK1 from its binding site on MCL1 By similarity. Competes with BIM/BCL2L11 for binding to MCL1 and can displace BIM/BCL2L11 from its binding site on MCL1.